Oral Desogestrel versus DMPA for empiric treatment in endometriosis

Oral desogestrel versus Depot Medroxyprogesterone Acetate treatment for non operative endometriosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180705001

Enrollment

180

Registered

2018-07-05

Start date

2018-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with endometriosis Endometriosis Desogestrel Depot medroxy progesterone acetate Quality of life

Interventions

Desogestrel(CerazetteÂ®)prescribe 1 tab/d for 3 months,Depot medroxy progesterone acetate (DMPA) prescribe 1 amp/months intramuscular injection for 3 months

Active Comparator Drug,Active Comparator Drug

Desogestrel,Depot medroxy progesterone acetate

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: -Diagnosed as endometriosis -No indication for surgical treatment

Exclusion criteria

Exclusion criteria: -Contraindication for proogestin contraception -Underlying disease which is not appropriate for progestin contraception -Plan to pregnant in 18 months -Deny to be recruited in the study

Design outcomes

Primary

Measure	Time frame
Efficiancy for control endometriosis symptoms 3 months Quality of life score(EQ-5D-5L), Visual analogue scale	—

Secondary

Measure	Time frame
Patient's satify and side effect of drug 3 months Questionairs,Changing of CA 125 level 3 months CA 125 level in blood	—

Countries

Thailand

Contacts

Public ContactPichavit Boonnum

Department of Obstetrics and Gynaecology, Faculty of Medicine, Chiangmai University

b.pichavit@gmail.com0875674671

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026